HomeStreet Inc.

Insider Buying Week 5-5-23 Banking Blood Bath is it time to Buy?

by

Insiders came out to play last week. It was not pretty, but insiders are bottom fishers, as a rule. They buy in force when prices are down when they perceive a bottom.  Regional bank insiders were all over the field scooping up prices that haven’t been seen since the Pandemic lows. Unfortunately, most of it was in regional bank stocks. Bank stocks are notoriously difficult to understand. First of all, they are highly leveraged, between 5-10% Tier 1 capital ratios which is the ratio of a bank’s core tier 1 capital—its equity capital and disclosed reserves—to its total risk-weighted assets.  Usually, that … Read more

‘s 5% Decline

by

  Curious how well insiders are doing with their buys? Scroll through the significant buys of the last year. The S&P 500 lost over 6% points last week after losing 5% in the previous week. Stocks don’t fall like this unless there is something really wrong. I’m trying to figure that out and the only thing that I can come up with is that the Fed has been bullied into raising interest rates into a weakening economy. Raising interest rates to bring down the price of oil or to untangle the supply chain disruptions is an act of lunacy.  The … Read more

Insider Buying Week 5-20-22 Trying to Go Up on a Down Escalator

by

  Curious how well insiders are doing with their buys? Scroll through the significant buys of the last year. I spent much of last weekend toiling over the Insiders Report.  Insider buying is picking up in the ruins of the NASDAQ but not enough to waive the all-clear flag that I described in the last post.  The  S&P 500 dipped into “bear” territory Friday only to stage a furious machine-driven short-covering rally that erased a 560 point decline in the last 30 minutes of the day.  Read on for the brave souls that keep trying to ride up the down … Read more

Insider Buying Picks Up Dramatically Week 8-06-21

by

For trade, details click on this link to the trades.  Name Sachs Bruce I Position: Director Shares Bought: 15,000 Average Price Paid: $197.91, Cost: $2,968,650 Company: Vertex Pharmaceuticals Inc. (VRTX) Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease – and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has … Read more